PERSPECTIVES IN CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Rational Helicobacter pylori Therapy: Evidence-Based Medicine Rather Than Medicine-Based Evidence

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance.

  2013cited by this paper
• Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.

  2013cited by this paper
• Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection.

  2013cited by this paper
• Comparison of Hybrid and Sequential Therapies for Helicobacter pylori Eradication in Iran: A Prospective Randomized Trial

  2013cited by this paper
• Helicobacter pylori: Tailored therapy with novel sequential quadruple therapies

  2013cited by this paper
• Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study.

  2013cited by this paper
• Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption

  2012cited by this paper
• Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection.

  2012cited by this paper
• Which Therapy for Helicobacter pylori Infection?

  2012cited by this paper
• Furazolidone in Helicobacter Pylori Therapy: Misunderstood and Often Unfairly Maligned Drug Told in A Story of French Bread

  2012cited by this paper
• Guide Regarding Choice of Second‐line Therapy to Obtain a High Cumulative Cure Rate

  2012cited by this paper
• Letter: the ethics of using inferior regimens in H. pylori randomised trials – editors’ reply

  2012cited by this paper
• Greater Than 95% Success with 14‐day Bismuth Quadruple Anti‐ Helicobacter pylori Therapy: A Pilot Study in US Hispanics

  2012cited by this paper
• Review article: rifabutin in the treatment of refractory Helicobacter pylori infection

  2012cited by this paper
• Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations

  2012cited by this paper
• Helicobacter pylori Therapy in the West.

  2012cited by this paper
• Pilot Studies to Identify the Optimum Duration of Concomitant Helicobacter pylori Eradication Therapy in Thailand

  2012cited by this paper
• Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report

  2012cited by this paper
• Modified Sequential Helicobacter pylori Therapy: Proton Pump Inhibitor and Amoxicillin for 14 Days with Clarithromycin and Metronidazole added as a Quadruple (Hybrid) Therapy for the Final 7 Days

  2011cited by this paper
• 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.

  2011cited by this paper
• Empiric therapies for Helicobacter pylori infections

  2011cited by this paper
• Twice‐a‐Day Bismuth‐Containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Trial of 10 and 14 Days

  2011cited by this paper
• Review article: non‐bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori

  2011cited by this paper
• Randomized Trial on 14 versus 7 days of Esomeprazole, Moxifloxacin, and Amoxicillin for Second‐line or Rescue Treatment of Helicobacter pylori Infection

  2011cited by this paper
• Optimal therapy for Helicobacter pylori infections

  2011cited by this paper
• Understanding and Appreciating Sequential Therapy for HelicobacterpyloriEradication

  2011cited by this paper
• Efficacy of 2‐Week, Second‐Line Helicobacter pylori Eradication Therapy Using Rabeprazole, Amoxicillin, and Metronidazole for the Japanese Population

  2011cited by this paper
• Follow-up testing after treatment of Helicobacter pylori infections: cautions, caveats, and recommendations.

  2011cited by this paper
• Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial

  2010cited by this paper
• Empiric Quadruple vs. Triple Therapy for Primary Treatment of Helicobacter pylori Infection: Systematic Review and Meta-Analysis of Efficacy and Tolerability

  2010cited by this paper
• Helicobacter pylori eradication therapy research: Ethical issues and description of results.

  2010cited by this paper
• Sequential Therapy for Helicobacter pylori Eradication: A Critical Review

  2010cited by this paper
• Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection.

  2010cited by this paper
• Gastric tubes as vectors of Helicobacter pylori transmission.

  2010cited by this paper
• Analysis of drug resistance and virulence‐factor genotype of Irish Helicobacter pylori strains: is there any relationship between resistance to metronidazole and cagA status?

  2009cited by this paper
• Sequential Therapy or Triple Therapy for Helicobacter pylori Infection: Systematic Review and Meta-Analysis of Randomized Controlled Trials in Adults and Children

  2009cited by this paper
• Meta-analysis: Sequential Therapy Appears Superior to Standard Therapy for Helicobacter pylori Infection in Patients Naive to Treatment

  2008cited by this paper
• Meta-analysis: Duration of First-Line Proton-Pump InhibitorBased Triple Therapy for Helicobacter pylori Eradication

  2007cited by this paper
• The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis

  2007cited by this paper
• Meta‐analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first‐line therapies for Helicobacter pylori

  2007cited by this paper
• Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy

  2007cited by this paper
• Efficacy and safety of rifabutin‐containing ‘rescue therapy’ for resistant Helicobacter pylori infection

  2006cited by this paper
• Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen.

  2006cited by this paper
• Twice‐A‐Day Quadruple Therapy for Eradication of Helicobacter pylori in the Elderly

  2006cited by this paper
• Smoking increases the treatment failure for Helicobacter pylori eradication.

  2006cited by this paper
• Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States.

  2004cited by this paper
• Etest for Metronidazole Susceptibility in H. pylori: Use of the Wrong Standard May Have Led to the Wrong Conclusion

  2004cited by this paper
• Management of Helicobacter pylori eradication--the influence of structured counselling and follow-up.

  2002cited by this paper
• Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori.

  2001cited by this paper
• cagA Status and Eradication Treatment Outcome of Anti-Helicobacter pylori Triple Therapies in Patients with Nonulcer Dyspepsia

  2001cited by this paper
• A new highly effective short‐term therapy schedule for Helicobacter pylori eradication

  2000cited by this paper
• Evaluation of treatment regimens to cure Helicobacter pylori infection—a meta‐analysis

  1999cited by this paper
• Prevalence of Antimicrobial Resistance in Eighty Clinical Isolates of Helicobacter pylori

  1999cited by this paper
• Intention‐to‐treat analysis and the goals of clinical trials

  1995cited by this paper

• An Open‐Label Randomized Controlled Trial Comparing the Efficacy and Safety of a 7‐Day Triple Therapy With Bismuth Versus 14‐Day Standard Triple Therapy for Helicobacter pylori Eradication in Children and Adolescents

  2026cites this paper
• Non‐Bismuth Quadruple Concomitant Treatment for Helicobacter pylori Eradication: A Systematic Review and Meta‐Analysis

  2026cites this paper
• WeChat-based manual enhanced guidance in patients with Helicobacter pylori infection

  2025cites this paper
• Declining eradication rates of Helicobacter pylori with standard triple therapy in Addis Ababa, Ethiopia

  2025cites this paper
• Tailored Therapy vs. Empirical Therapy for Helicobacter pylori Eradication: An Umbrella Review of Systematic Reviews and Meta-Analyses

  2025cites this paper
• Treatment and Follow-Up of Patients With Helicobacter pylori Infection in Primary Health Care: A Retrospective Multicenter Study

  2025cites this paper
• Design, synthesis, and in-Silco ADME prediction of some novel bis(1,3,4-thiadiazoles) encapsulated lipid chitosan nano capsule decorative with magnetic nanoparticles and their potential anti-helicobacter pylori activity.

  2025cites this paper
• Prospective Randomised Study of a 14 day Clarithromycin Triple Regimen and a 14 Day Bismuth based Quadruple Regimen for Helicobacter Pylori Eradication.

  2025cites this paper
• Helicobacter pylori eradication rate following first line non-bismuth quadruple therapy regimen in Tunisian patients: the HPERAD study

  2025cites this paper
• Comprehensive insights on treatment modalities with conventional and herbal drugs for the treatment of duodenal ulcers

  2024cites this paper
• Prevalence, Management, and Outcomes of Non-Invasive Helicobacter pylori Testing in Children at a Tertiary Paediatric Hospital in Singapore

  2024cites this paper
• Comparison of the Efficacy of 12-day Concomitant Quadruple Therapy versus 14-day High dose Dual Therapy as a First-line H. pylori Eradication Regimen

  2024cites this paper
• Erradicación de Helicobacter pylori con tratamiento de primera línea en un hospital de alta complejidad del suroccidente colombiano

  2024cites this paper
• Genetic Determinants of Clarithromycin and Fluoroquinolones Resistance in Helicobacter pylori in Serbia

  2024cites this paper
• Effectiveness of First-Line Empirical Treatment in Portugal: Data from the European Registry on Helicobacter pylori Management

  2024influential citation
• Helicobacter pylori-targeted AI-driven vaccines: a paradigm shift in gastric cancer prevention

  2024cites this paper
• Modern approaches to the treatment of peptic ulcer disease and prospects for the use of biological therapy

  2023cites this paper
• Tailored triple plus bismuth therapy based on previous antibiotic medication history for first-line Helicobacter pylori eradication: A randomized trial.

  2023cites this paper
• 헬리코박터 파일로리 제균 치료: 근거 중심 치료를 기본 치료로

  2023cites this paper
• Assessment of Anti-Helicobacter Pylori Eradication Regimens in Basrah Gastroenterology and Hepatology Hospital

  2023cites this paper
• Combination of gastroprotectors and probiotics in the eradication of H. pylori infection: results of a randomized comparative clinical trial

  2023cites this paper
• Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial

  2023cites this paper
• New regimens as first‐line eradication therapy for Helicobacter pylori infection in patients allergic to penicillin: A randomized controlled trial

  2023cites this paper
• Clarithromycin-based Helicobacter pylori eradication therapy is not associated with higher treatment failure compared with non-clarithromycin-based regimens in a tertiary referral hospital in Switzerland.

  2023cites this paper
• Determination of Helicobacter pylori resistance to clarithromycin in biopsy samples of gastric mucosa using TaqMan® MGB probes

  2023cites this paper
• Individualized diagnosis and eradication therapy for Helicobacter pylori infection based on gene detection of clarithromycin resistance in stool specimens: A systematic review and meta‐analysis

  2023cites this paper
• Eradicating Helicobacter pylori via 13C-urea breath screening to prevent gastric cancer in indigenous communities: a population-based study and development of a family index-case method

  2023cites this paper
• Modern approaches to the treatment of peptic ulcer disease and prospects for the use of biological therapy

  2023cites this paper
• Empiric use of standard triple therapy in Helicobacter pylori eradication does not require readjustment in the clarithromycin resistance cut-off point

  2023cites this paper
• Clarithromycin-induced acute liver injury in a patient with positive Helicobacter pylori: a case report and review of the literature

  2023cites this paper
• The epidemiology of Helicobacter pylori resistance in a university affiliated hospital: a comparison between two time periods—a cross-sectional design

  2023cites this paper
• Tratamiento de primera línea para erradicación de Helicobacter pylori: todavía una terapia eficaz

  2023cites this paper
• Prospective Study of Vonoprazan-Based First-Line Triple Therapy with Amoxicillin and Metronidazole for Clarithromycin-Resistant Helicobacter pylori

  2023cites this paper
• Helicobacter pylori Infections in Children

  2023cites this paper
• Antibiotic Resistance, Susceptibility Testing and Stewardship in Helicobacter pylori Infection

  2023cites this paper
• Effectiveness of eradication therapy for Helicobacter pylori infection in Africa: a systematic review and meta-analysis

  2023cites this paper
• Multidrug resistance in Helicobacter pylori infection

  2023cites this paper
• Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on Helicobacter pylori Management (Hp-EuReg)

  2023cites this paper
• Therapeutic eradication choices in Helicobacter pylori infection in children

  2023cites this paper
• Short-term outcomes and intermediate-term follow-up of Helicobacter pylori infection treatment for naïve patients: a retrospective observational study

  2022cites this paper
• Evaluation of the Potential Protective Effects of Lactobacillus Strains against Helicobacter pylori Infection: A Randomized, Double-Blinded, Placebo-Controlled Trial

  2022cites this paper
• Modern opportunities to improve the effectiveness of eradication therapy on a clinical case

  2022cites this paper
• Susceptibility-Guided Therapy vs. Bismuth-Containing Quadruple Therapy as the First-Line Treatment for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis

  2022cites this paper
• Susceptibility testing alone will not reliably achieve high Helicobacter pylori cure rates: A systematic review and meta‐analysis

  2022cites this paper
• Susceptibility-guided vs. empirical 10-day quadruple treatment for Helicobacter pylori-infected patients: A prospective clinical trial of first-line therapy

  2022cites this paper
• Нow to increase the effectiveness of eradication therapy of Helicobacter pylori infection?

  2022cites this paper
• The Efficacy of Probiotics in Treatment of Helicobacter

  2022cites this paper
• Community prevalence of Helicobacter pylori and dyspepsia and efficacy of triple therapy in a rural district of eastern Uganda

  2022cites this paper
• The Importance of Accurate Early Diagnosis and Eradication in Helicobacter pylori Infection: Pictorial Summary Review in Children and Adults

  2022cites this paper
• Increased Antibiotic Resistance in Children with Helicobacter pylori Infection: A Retrospective Study

  2022cites this paper
• Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first‐line regimen for Helicobacter pylori eradication: A randomized controlled trial

  2022cites this paper
• The efficacy of bismuth quadruple therapy, sequential therapy, and hybrid therapy as a first-line regimen for Helicobacter pylori infection compared with standard triple therapy

  2022cites this paper
• Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg)

  2022cites this paper
• Current Trends in the Management of Helicobacter pylori Infection in Serbia: Preliminary Results from the European Registry on H. pylori Management

  2022cites this paper
• Mass screening and eradication of Helicobacter pylori as the policy recommendations for gastric cancer prevention.

  2022cites this paper
• European Registry on Helicobacter pylori Management (Hp-EuReg): Most relevant results for clinical practice

  2022cites this paper
• A randomized controlled trial to compare Helicobacter pylori eradication rates between the empirical concomitant therapy and tailored therapy based on 23S rRNA point mutations

  2022cites this paper
• Effect of metronidazole resistance on Helicobacter pylori eradication regimens

  2022cites this paper
• Comparative Effectiveness of Various Eradication Regimens for Helicobacter Pylori Infection in the Northeastern Region of Poland

  2022cites this paper
• Fourteen-day sequential therapy is superior to 7-day triple therapy as first-line regimen for Helicobacter pylori infected children.

  2021cites this paper
• Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice

  2021cites this paper
• Antibiotic resistance patterns and therapeutic outcomes of pediatric Helicobacter pylori infection in a high‐migrant Singaporean cohort

  2021cites this paper
• The effect of previous eradication failure on antibiotic resistance of Helicobacter pylori: A retrospective study over 8 years in Beijing

  2021cites this paper
• V Spanish Consensus Conference on Helicobacter pylori infection treatment.

  2021cites this paper
• V Spanish Consensus Conference on Helicobacter pylori infection treatment.

  2021cites this paper
• Helicobacter pylori in Childhood

  2021cites this paper
• Prospectives of Helicobacter pylori

  2021cites this paper
• The status and progress of first-line treatment against Helicobacter pylori infection: a review

  2021cites this paper
• 10‐Day and 14‐day high‐dose dual therapy for the treatment of Helicobacter pylori: A propensity score matching analysis

  2021cites this paper
• Helicobacter pylori infection and antibiotic resistance — from biology to clinical implications

  2021cites this paper
• Comparison of Furazolidone Versus Clarithromycin for Eradication of Helicobacter Pylori Infection: A ‎Randomized Multicenter Clinical Trial ‎

  2021cites this paper
• Evaluation of the Effectiveness of Helicobacter pylori Eradication Regimens in Lithuania during the Years 2013–2020: Data from the European Registry on Helicobacter pylori Management (Hp-EuReg)

  2021cites this paper
• Co-delivery of hesperidin and clarithromycin in a nanostructured lipid carrier for the eradication of Helicobacter pylori in vitro.

  2021cites this paper
• Assessment of first-line eradication treatment in Greece: data from the European Registry on Helicobacter pylori management (Hp-EuReg)

  2021cites this paper
• Guality eradication anti-helicobacter therapy increases the effectiveness of treatment of patients with stable angina pectoris

  2021cites this paper
• The Current Strategy of Helicobacter pylori Eradication

  2021cites this paper
• Evaluating treatments with rifabutin and amoxicillin for eradication of Helicobacter pylori infection in adults: a systematic review

  2021cites this paper
• СОВРЕМЕННОЕ РАЗВИТИЕ СХЕМ ЭРАДИКАЦИИ HELICOBACTER PYLORI

  2021cites this paper
• Salvage Regimens after Failure of Previous Helicobacter pylori Eradication Therapy: A Systematic Review and Meta-analysis

  2021cites this paper
• Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial

  2021cites this paper
• Effect of probiotics during vonoprazan‐containing triple therapy on gut microbiota in Helicobacter pylori infection: A randomized controlled trial

  2020cites this paper
• Nuevas recomendaciones para el diagnóstico y tratamiento de la infección por Helicobacter pylori en niños

  2020cites this paper
• Susceptibility‐guided therapy for Helicobacter pylori‐infected penicillin‐allergic patients: A prospective clinical trial of first‐line and rescue therapies

  2020cites this paper
• Helicobacter pylori: A Review of Current Diagnostic and Management Strategies

  2020cites this paper
• Development and Evaluation of Amoxicillin Loaded Carbopol 934P Mucoadhesive Microcapsules for Sustained Drug Release for H. pylori Treatment

  2020cites this paper
• Clarithromycin Versus Metronidazole in First-Line Helicobacter Pylori Triple Eradication Therapy Based on Resistance to Antimicrobial Agents: Meta-Analysis

  2020cites this paper
• Hellenic consensus on Helicobacter pylori infection

  2020cites this paper
• Comparison of four different regimens against Helicobacter pylori as a first‐line treatment: A prospective, cross‐sectional, comparative, open trial in Chinese children

  2020cites this paper
• The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance

  2020cites this paper
• Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: A systematic review and meta-analysis.

  2020cites this paper
• Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea: 2020 Revised Edition

  2020cites this paper
• Европейский регистр ведения инфекции Helicobacter pylori: особенности диагностики и лечения в Казани

  2020cites this paper
• A Randomised Trial Comparing 10-Day Sequential and 14-Day Triple Drug Therapy in Eradication of Helicobacter pylori in Patients with RUT Positive Antral Gastritis

  2020cites this paper
• Reverse hybrid therapy achieves a similar eradication rate as standard hybrid therapy for Helicobacter pylori infection

  2020cites this paper
• Effect of Saccharomyces boulardii CNCM I-745 as complementary treatment of Helicobacter pylori infection on gut microbiome

  2020cites this paper
• European Registry on Helicobacter pylori management: Single‐capsule bismuth quadruple therapy is effective in real‐world clinical practice

  2020cites this paper
• [European Registry on the management of Helicobacter pylori infection: features of diagnosis and treatment in Kazan].

  2020cites this paper
• Vitamin C does not improve the efficacy of Helicobacter pylori eradication in smokers

  2020cites this paper
• [Antibiotic resistance of Helicobacter pylori in the European part of the Russian Federation: first results].

  2020cites this paper
• An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection

  2020cites this paper